Prot # GS-US-337-0109: A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5885 Fixed-Dose Combination ± Ribavirin for 12 and 24 Weeks in Treatment-Experienced Subjects with Chronic Genotype 1 HCV I

Project: Research project

Project Details

Effective start/end date1/4/131/4/17


  • PRA Health Sciences (GS-US-337-0109 // GS-US-337-0109)
  • Gilead Sciences, Inc (GS-US-337-0109 // GS-US-337-0109)